WD Rutherford LLC Acquires 1,035 Shares of Boston Scientific Co. (NYSE:BSX)

WD Rutherford LLC boosted its stake in shares of Boston Scientific Co. (NYSE:BSX) by 22.4% during the fourth quarter, according to the company in its most recent filing with the Securities & Exchange Commission. The fund owned 5,646 shares of the medical equipment provider’s stock after acquiring an additional 1,035 shares during the quarter. WD Rutherford LLC’s holdings in Boston Scientific were worth $504,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also recently added to or reduced their stakes in BSX. Creative Planning grew its stake in shares of Boston Scientific by 7.7% during the third quarter. Creative Planning now owns 204,208 shares of the medical equipment provider’s stock valued at $17,113,000 after purchasing an additional 14,663 shares during the last quarter. Global Retirement Partners LLC boosted its position in Boston Scientific by 11.5% in the 3rd quarter. Global Retirement Partners LLC now owns 4,370 shares of the medical equipment provider’s stock valued at $366,000 after buying an additional 449 shares during the last quarter. Sumitomo Mitsui DS Asset Management Company Ltd increased its stake in shares of Boston Scientific by 2.0% in the 3rd quarter. Sumitomo Mitsui DS Asset Management Company Ltd now owns 172,494 shares of the medical equipment provider’s stock valued at $14,455,000 after buying an additional 3,433 shares during the period. V Square Quantitative Management LLC raised its position in shares of Boston Scientific by 20.8% during the third quarter. V Square Quantitative Management LLC now owns 11,133 shares of the medical equipment provider’s stock worth $933,000 after acquiring an additional 1,914 shares during the last quarter. Finally, Stonegate Investment Group LLC lifted its stake in shares of Boston Scientific by 7.5% during the third quarter. Stonegate Investment Group LLC now owns 7,701 shares of the medical equipment provider’s stock valued at $645,000 after acquiring an additional 534 shares during the period. Institutional investors and hedge funds own 89.07% of the company’s stock.

Insider Buying and Selling at Boston Scientific

In related news, EVP Arthur C. Butcher sold 14,010 shares of Boston Scientific stock in a transaction dated Monday, November 25th. The stock was sold at an average price of $89.27, for a total value of $1,250,672.70. Following the sale, the executive vice president now owns 978 shares of the company’s stock, valued at approximately $87,306.06. The trade was a 93.47 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through the SEC website. Also, CFO Daniel J. Brennan sold 15,087 shares of the stock in a transaction that occurred on Wednesday, February 12th. The shares were sold at an average price of $105.07, for a total value of $1,585,191.09. Following the transaction, the chief financial officer now directly owns 241,451 shares of the company’s stock, valued at $25,369,256.57. This trade represents a 5.88 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last quarter, insiders have sold 87,326 shares of company stock worth $8,673,948. Corporate insiders own 0.50% of the company’s stock.

Analysts Set New Price Targets

A number of analysts recently commented on BSX shares. Barclays lifted their price objective on Boston Scientific from $111.00 to $118.00 and gave the stock an “overweight” rating in a research report on Monday, February 10th. UBS Group boosted their price target on shares of Boston Scientific from $105.00 to $130.00 and gave the stock a “buy” rating in a research note on Friday, February 7th. JPMorgan Chase & Co. increased their price objective on shares of Boston Scientific from $100.00 to $110.00 and gave the company an “overweight” rating in a report on Monday, December 16th. Truist Financial upped their target price on shares of Boston Scientific from $100.00 to $110.00 and gave the company a “buy” rating in a research report on Wednesday, December 18th. Finally, Stifel Nicolaus increased their price target on Boston Scientific from $100.00 to $115.00 and gave the company a “buy” rating in a research note on Thursday, February 6th. One analyst has rated the stock with a hold rating, twenty-two have assigned a buy rating and one has given a strong buy rating to the company. According to data from MarketBeat.com, the company has an average rating of “Buy” and an average price target of $107.39.

Boston Scientific Trading Up 0.1 %

Shares of NYSE:BSX opened at $106.20 on Friday. The firm has a market cap of $156.51 billion, a price-to-earnings ratio of 84.96, a PEG ratio of 2.79 and a beta of 0.80. The company has a quick ratio of 1.02, a current ratio of 1.48 and a debt-to-equity ratio of 0.44. Boston Scientific Co. has a 12 month low of $65.33 and a 12 month high of $107.17. The company’s fifty day simple moving average is $96.44 and its 200 day simple moving average is $88.19.

Boston Scientific (NYSE:BSX) last issued its quarterly earnings results on Wednesday, February 5th. The medical equipment provider reported $0.70 EPS for the quarter, beating analysts’ consensus estimates of $0.65 by $0.05. Boston Scientific had a return on equity of 18.11% and a net margin of 11.07%. As a group, research analysts forecast that Boston Scientific Co. will post 2.83 EPS for the current fiscal year.

Boston Scientific Company Profile

Boston Scientific Corporation develops, manufactures, and markets medical devices for use in various interventional medical specialties worldwide. It operates through two segments, MedSurg and Cardiovascular. The company offers devices to diagnose and treat gastrointestinal and pulmonary conditions, such as resolution clips, biliary stent systems, stents and electrocautery enhanced delivery systems, direct visualization systems, digital catheters, and single-use duodenoscopes; devices to treat urological conditions, including ureteral stents, catheters, baskets, guidewires, sheaths, balloons, single-use digital flexible ureteroscopes, holmium laser systems, artificial urinary sphincter, laser system, fiber, and hydrogel systems; and devices to treat neurological movement disorders and manage chronic pain, such as spinal cord stimulator system, proprietary programming software, radiofrequency generator, indirect decompression systems, practice optimization tools, and deep brain stimulation system.